Protein A Chromatography Multi-scale Data Driven/Mechanistic Modeling (Phase 2)

Develop a hybrid modeling infrastructure for simulating protein A chromatography performance and predicting process/product related impurities in the manufacture of monoclonal antibodies
Categories
Drug substance
Process control
Data
Project status
100% Completed

Industry Need

There is a need for modeling infrastructure for simulating the performance of one of the two initial downstream steps in the manufacture of monoclonal antibodies (mAbs), namely protein A (ProA) chromatography. Being able to describe and predict the values of key outputs that are routinely measured and assayed in process development and manufacturing applications of these operations are very helpful. There is a need for readily usable models by industry practitioners and the models being adaptable by them, using well-defined procedures for determining model parameters, for application to systems using different mAbs, process streams and separations media. Mechanistic models of column chromatography have been developed for many decades and their solution has been streamlined over the past decade by the availability of modeling packages for solving the relevant equations, but validated approaches for robustly capturing all aspects of column behavior in detail are surprisingly sparse.

Solution

Mechanistic modeling functions on the premise that assumptions made about the transport and equilibrium processes of the system describe the system well and can be used to represent the system in most process conditions under a range of industrial scales and resin lifetimes. Such models can be very effective for describing and predicting behavior in response to many changes in structural (e.g., column length or diameter) or operating (flow velocity, pH) conditions, other known but often subtler changes are less easy to characterize or predict. In order to integrate such, potentially important, effects into our models, they will be augmented into hybrid models. One alternative approach is to use an artificial neural network that learns to depict and update the isotherm and transport parameters based on measured column data. This can provide additional degrees of freedom to the isotherm and mass transfer relationships, untied from mechanistic assumptions and enable ongoing model learning from diverse settings and processes in real time. It can also be important in describing the behavior of incompletely characterized impurities. In this project software is developed that will employ both mechanistic and hybrid modeling to predict protein A chromatographic behavior in a variety of settings

Outputs/Deliverables

1. Poster complete Experimental and mechanistic modeling techniques to examine pH transitions in protein a step elution Angela R. Moser, Soumitra Bhoyar, Scott H. Altern, R. Helen Zha, Abraham M. Lenhoff, Steven M. Cramer PREP 2024

2. Presentation accepted Investigating pH transitions for mechanistic modeling of protein A step elution Angela R. Moser, Soumitra Bhoyar, Scott H. Altern, R. Helen Zha, Abraham M. Lenhoff, Steven M. Cramer ACS BIOT 2025

3. Poster accepted Efficient parameter estimation strategy for pH dependent mechanistic modeling of protein A chromatography Angela R. Moser, Soumitra Bhoyar, Scott H. Altern, R. Helen Zha, Abraham M. Lenhoff, Steven M. Cramer (also possibly BMS collaborators) 6th Mini Modeling Workshop (2025)

4. Publication planned (not started)


Impacts

Reduce process development time and cost of Antibody products

Additional Project Information (Members Only)

Login to the NIIMBL member portal to access more, including: 

  • Updates
  • Value Proposition
  • Related Publications
  • Deliverables

Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.

Project Lead

Rensselaer Polytechnic Institute

Rensselaer Polytechnic Institute

Participating Organizations

AstraZeneca

AstraZeneca

Boehringer Ingelheim

Boehringer Ingelheim

Bristol-Myers Squibb

Bristol-Myers Squibb

Cytiva

Cytiva

Federal Stakeholder:  National Institute of Standards and Technology

Federal Stakeholder: National Institute of Standards and Technology

Genentech, Inc.

Genentech, Inc.

Merck Sharp & Dohme LLC

Merck Sharp & Dohme LLC

MilliporeSigma/EMD Serono

MilliporeSigma/EMD Serono

NIIMBL

NIIMBL

Pfizer, Inc.

Pfizer, Inc.

Sanofi

Sanofi